Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746386 | 0.76 | CNR2 (0.35) | THRBZAP70SYKKDM4EGAA | |
| SCHEMBL26791923 | 0.76 | TRPM8 (0.38) | THRBPOLBLMNAALDH1A1RAB9A | |
| SCHEMBL3742906 | 0.76 | ALDH1A1 (0.45) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3749715 | 0.76 | ALDH1A1 (0.45) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3751397 | 0.75 | KDM4E (0.46) | POLBLMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL3743362 | 0.75 | TLR8 (0.37) | THRB | |
| SCHEMBL3749711 | 0.74 | SCN9A (0.35) | LMNAALDH1A1KDM4EGAATDP1 | |
| SCHEMBL3751929 | 0.73 | ROCK2 (0.48) | RAB9AKMT2A | |
| SCHEMBL26795528 | 0.73 | TRPM8 (0.39) | POLBLMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL3744085 | 0.72 | P2RX7 (0.39) | THRBLMNAKDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | THRB 225/4885ZAP70 2822/4885SYK 3450/4885 |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | THRB 225/4885ZAP70 2822/4885SYK 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.